How genetic differences affect the effectiveness of emergency contraception
Disparities in emergency contraceptive metabolism dictate efficacy
This study is looking at how differences in genes, especially one called CYP3A5, might affect how well emergency contraceptives like ulipristal acetate work for women of color, with the goal of understanding why some groups may have higher rates of contraceptive failure and finding ways to create more personalized options for them.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Oregon Health & Science University NIH-funded |
| Lab location | 1 site (Portland, United States) |
| Project ID | NIH-10852956 on NIH RePORTER |
What this research studies
This research investigates how genetic variations, particularly in the CYP3A5 enzyme, influence the effectiveness of emergency contraceptives like ulipristal acetate in women of color. It aims to understand the disparities in contraceptive failure rates among different racial groups, focusing on the pharmacogenomic factors that may contribute to these differences. By analyzing blood samples and genetic data, the study seeks to identify why certain populations may experience reduced efficacy from standard contraceptive doses. The findings could lead to more personalized contraceptive options based on genetic profiles.
Who could benefit from this research
Good fit: Ideal candidates for this research are women of color who are seeking emergency contraception and may have experienced contraceptive failure.
Not a fit: Patients who do not identify as women of color or those who have not used emergency contraception may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to improved emergency contraceptive options tailored to the genetic profiles of women, reducing unintended pregnancies.
How similar studies have performed: Other research has shown that pharmacogenomic differences can significantly affect drug metabolism and efficacy, suggesting that this approach may yield valuable insights.
Where this research is happening
Portland, United States
- Oregon Health & Science University — Portland, United States (Active)
Researchers
- Principal investigator: Edelman, Alison B — Oregon Health & Science University
- Study coordinator: Edelman, Alison B
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.